{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T02:51:25Z","timestamp":1780541485673,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.mehy.2010.07.024","type":"journal-article","created":{"date-parts":[[2010,8,13]],"date-time":"2010-08-13T09:14:00Z","timestamp":1281690840000},"page":"544-546","source":"Crossref","is-referenced-by-count":35,"title":["Bupropion as the treatment of choice in depression associated with Parkinson\u2019s disease and it\u2019s various treatments"],"prefix":"10.1016","volume":"75","author":[{"given":"Sergey","family":"Raskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimona","family":"Durst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2010.07.024_bib1","series-title":"Neuropsychiatry and clinical neurosciences","author":"Yudofsky","year":"2002"},{"key":"10.1016\/j.mehy.2010.07.024_bib2","first-page":"561","article-title":"Parkinsons\u2019s disease in a population group in northern Norway","volume":"109","author":"Bekkelund","year":"1989","journal-title":"Tidsskr Nor Laegeforen"},{"key":"10.1016\/j.mehy.2010.07.024_bib3","series-title":"Synopsis of psychiatry","author":"Kaplan","year":"1998"},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2010.07.024_bib4","first-page":"S65","article-title":"Nonmotor manifestations of Parkinson\u2019s disease","volume":"64","author":"Simuni","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.mehy.2010.07.024_bib5","series-title":"Synopsis of psychiatry","author":"Kaplan","year":"1994"},{"key":"10.1016\/j.mehy.2010.07.024_bib6","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/00002826-199501001-00008","article-title":"A dopaminergic hypothesis of major depression","volume":"18","author":"Mann","year":"1995","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"10.1016\/j.mehy.2010.07.024_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cne.902870308","article-title":"Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson\u2019s disease with and without dementia and depression","volume":"287","author":"Chan-Palay","year":"1989","journal-title":"J Comp Neurol"},{"issue":"3","key":"10.1016\/j.mehy.2010.07.024_bib8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s11920-006-0029-8","article-title":"Treatment of depression in Parkinson\u2019s disease","volume":"8","author":"Menza","year":"2006","journal-title":"Curr Psychiatry Rep"},{"issue":"10","key":"10.1016\/j.mehy.2010.07.024_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1212\/01.wnl.0000336340.89821.b3","article-title":"A controlled trial of antidepressants in patients with Parkinson disease and depression","volume":"72","author":"Menza","year":"2009","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.mehy.2010.07.024_bib10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1176\/appi.neuropsych.17.3.310","article-title":"Prevalence and treatment of depression in Parkinson\u2019s disease","volume":"17","author":"Veazey","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"6","key":"10.1016\/j.mehy.2010.07.024_bib11","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1345\/aph.17302","article-title":"Selective serotonin-reuptake inhibitor-induced movement disorders","volume":"32","author":"Gerber","year":"1998","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.mehy.2010.07.024_bib12","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/mds.10114","article-title":"Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson\u2019s disease","volume":"17","author":"Burn","year":"2002","journal-title":"Movement Disord"},{"issue":"2","key":"10.1016\/j.mehy.2010.07.024_bib13","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.pnpbp.2004.11.023","article-title":"Remarkable effect of milnacipran, a serotonin\u2013noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson\u2019s disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports","volume":"29","author":"Takahashi","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.mehy.2010.07.024_bib14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4088\/JCP.v63n0405","article-title":"Effect of reboxetine on depression in Parkinson\u2019s disease patients","volume":"63","author":"Lemke","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.mehy.2010.07.024_bib15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1002\/mds.20555","article-title":"Antidepressant studies in Parkinson\u2019s disease: a review and meta-analysis","volume":"20","author":"Weintraub","year":"2005","journal-title":"Movement Disord"},{"issue":"2","key":"10.1016\/j.mehy.2010.07.024_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1353-8020(03)00108-1","article-title":"Systematic review of antidepressant therapies in Parkinson\u2019s disease","volume":"10","author":"Chung","year":"2003","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"10.1016\/j.mehy.2010.07.024_bib17","first-page":"110","article-title":"Current issues in depression in Parkinson\u2019s disease","volume":"7","author":"Zesiewicz","year":"1999","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2010.07.024_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0404.2006.00536.x","article-title":"Depression in Parkinson\u2019s disease \u2013 a review","volume":"113","author":"Lieberman","year":"2006","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.mehy.2010.07.024_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/jnnp.66.4.541","article-title":"Affective symptoms in multiple system atrophy and Parkinson\u2019s disease: response to levodopa therapy","volume":"66","author":"Fetoni","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2010.07.024_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-510X(99)00198-7","article-title":"The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson\u2019s disease","volume":"172","author":"Choi","year":"2000","journal-title":"J Neurol Sci"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2010.07.024_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mds.870080508","article-title":"Symptomatic effect of selegiline in de novo parkinsonian patients. The French selegiline multicenter trial","volume":"8","author":"Allain","year":"1993","journal-title":"Movement Disord"},{"key":"10.1016\/j.mehy.2010.07.024_bib22","first-page":"505","article-title":"Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson\u2019s disease","volume":"vol. 80","author":"Steur","year":"1999"},{"key":"10.1016\/j.mehy.2010.07.024_bib23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1212\/WNL.48.4.1070","article-title":"Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson\u2019s disease. Parkinson study group","volume":"48","author":"Richard","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2010.07.024_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1468-1331.2003.00612.x","article-title":"Pramipexole and pergolide in the treatment of depression in Parkinson\u2019s disease: a national multicenter prospective randomized study","volume":"10","author":"Rektorova","year":"2003","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.mehy.2010.07.024_bib25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H","article-title":"Comparison of pramipexole, flioxetine and placebo in patients with major depression","volume":"11","author":"Corrigan","year":"2000","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.mehy.2010.07.024_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10401230009147102","article-title":"Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review","volume":"12","author":"Sporn","year":"2000","journal-title":"Ann Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.mehy.2010.07.024_bib27","first-page":"15","article-title":"The relevance of dopamine agonists in the treatment of depression","volume":"23","author":"Clausius","year":"2009","journal-title":"Neuropsychiatry"},{"issue":"Suppl. 2","key":"10.1016\/j.mehy.2010.07.024_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1468-1331.2008.02213.x","article-title":"Dopamine agonists in the treatment of non-motor symptoms of Parkinson\u2019s disease: depression","volume":"15","author":"Lemke","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.mehy.2010.07.024_bib29","first-page":"458","article-title":"Subthalamic stimulation for Parkinson\u2019s disease","volume":"7","author":"Israel","year":"2005","journal-title":"IMAJ"},{"issue":"9","key":"10.1016\/j.mehy.2010.07.024_bib30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.lpm.2008.11.019","article-title":"Deep brain stimulation, Parkinson\u2019s disease and neuropsychiatric complications","volume":"38","author":"Jaafari","year":"2009","journal-title":"Presset Med"},{"key":"10.1016\/j.mehy.2010.07.024_bib31","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1001\/archpsyc.60.3.296","article-title":"Deep brain stimulation of the subthalamic nucleus enhanced emotional processing in Parkinson\u2019s disease","volume":"60","author":"Schneider","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.mehy.2010.07.024_bib32","doi-asserted-by":"crossref","first-page":"845","DOI":"10.4088\/JCP.v65n0617","article-title":"Psychiatric complications of deep brain stimulation for Parkinson\u2019s disease","volume":"65","author":"Piasecki","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.mehy.2010.07.024_bib33","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/jnnp.2002.009803","article-title":"Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behavior in Parkinson\u2019s disease","volume":"75","author":"Funkiewiez","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.mehy.2010.07.024_bib34","series-title":"Synopsis of psychiatry","author":"Kaplan","year":"1998"},{"issue":"4","key":"10.1016\/j.mehy.2010.07.024_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4088\/PCC.v06n0403","article-title":"A review of the neuropharmacology of bupropion, a dual norepinephrin and dopamine reuptake inhibitor","volume":"6","author":"Stahl","year":"2004","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.mehy.2010.07.024_bib36","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1212\/WNL.34.8.1092","article-title":"Bupropion in Parkinson\u2019s disease","volume":"34","author":"Goetz","year":"1984","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.mehy.2010.07.024_bib37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3109\/10401239709147768","article-title":"Retrospective study of selegiline\u2013antidepressant drug interactions and a review of the literature","volume":"9","author":"Ritter","year":"1997","journal-title":"Ann Clin Psychiatry"},{"issue":"45","key":"10.1016\/j.mehy.2010.07.024_bib38","first-page":"2157","article-title":"Successful treatment of depression in Parkinson\u2019s disease patient with bupropion","volume":"144","author":"Leentjens","year":"2000","journal-title":"Ned Tijdschr Geeeskd"},{"key":"10.1016\/j.mehy.2010.07.024_bib39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00001648-199905000-00023","article-title":"Epidemiologic approaches to the study of Parkinson\u2019s disease etiology","volume":"10","author":"Checkoway","year":"1999","journal-title":"Epidemiology"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987710002628?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987710002628?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T21:59:09Z","timestamp":1544306349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987710002628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0306987710002628"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2010.07.024","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}